

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Irun R. COHEN et al.

Serial No. : 10/591,558

Cnfrm. No. : 3088

Filed : June 8, 2007

Title : CD25 DNA VACCINES FOR TREATING AND
PREVENTING T-CELL MEDIATED DISEASES

Examiner:
Marcia S. Noble

Art Unit:
1632

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97(c)(1) and (e)**

Mail Stop AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97, and 1.98, applicants hereby make of record in the instant application the documents listed on the PTO/SB/08 Form being submitted herewith.

The references cited in the accompanying PTO/SB/08 Form were cited by the European Searching Authority in the Supplementary European Search Report under Article 153(7) for European Patent Application No. 05709157, National Phase of PCT/IL2005/000273 (WO2005/084137), having a date of mailing of November 4, 2008. *Copies of the two cited references are being submitted herewith.*

This Supplemental Information Disclosure Statement is being filed prior to the mailing of a final office action. Further, pursuant to 37 C.F.R. § 1.97(e)(1), applicants state that each item of information contained in the attached PTO/SB/08 Form was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. Therefore, under 37 C.F.R. §§ 1.97(c)(1) and 1.97(e)(1),

applicants respectfully submit that *no fee* is due with regard to this Supplemental Information Disclosure Statement.

Applicants respectfully request that the Examiner consider completely the cited information, initial, sign, and date the enclosed PTO/SB/08 Form, and return a copy of the signed PTO/SB/08 Form with the next U.S. Patent and Trademark Office communication to evidence that the cited information has been fully considered by the U.S. Patent and Trademark Office during the examination of this application.

By citing these references, applicants make *no* representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b); and (3) the information cited is, or is considered to be, in fact, prior art as defined by 35 U.S.C. § 102.

The Commissioner is hereby authorized to charge payment of any additional fees that may be required, or credit any overpayment of same, to Deposit Account No. 08-1935.

Respectfully submitted,

HESLIN ROTHENBERG FARLEY & MESITI P.C.

By: **/Andrew K. Gonsalves/**

Dated: **December 21, 2008**

Andrew K. Gonsalves
Registration No. 48,145
Customer No. 23,405

Heslin Rothenberg Farley & Mesiti P.C.

5 Columbia Circle

Albany, NY 12203

Telephone: 518-452-5600

Facsimile: 518-452-5579

E-Mail: akg@hrfmlaw.com